

Patent for the production of Immunicum's therapeutic cancer vaccines to be granted in Europe

GOTHENBURG, January 27, 2015. Immunicum AB (publ) today announced that the European Patent Office (EPO) has announced its intention to grant a patent pertaining to the production method of the Company's therapeutic cancer vaccines.

– We are pleased with the positive news from the European Patent Office, which will further strengthen the intellectual property protection for our therapeutic cancer vaccines, says Jamal El-Mosleh, CEO of Immunicum.

The announcement from the EPO relates to a patent titled “*Co-Differentiation Of Monocytes From Allogeneic Donors*”, covering a significant part of the production method of Immunicum's therapeutic cancer vaccines.

Immunicum's vaccine cells are comprised of white blood cells from healthy blood donors, so-called allogeneic dendritic cells, which via a unique refinement process are developed into highly immunogenic cells. The Company's unique vaccine concept is based on over 30 years of research in the field of transplantation immunology and uses a new method to activate the body's own immune system to attack tumor cells.

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com

The company's Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se

About Immunicum AB (publ)

Immunicum AB (publ) develops vaccines for the treatment of tumor diseases. A phase II study of the company's most advanced project - INTUVAX[®] against renal cancer - is expected to start in early 2015. The project portfolio contains three further projects, including a clinical phase I/II-study in liver cancer.

www.immunicum.com